NewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by US Bancorp DE

US Bancorp DE lessened its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 80.6% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 2,804 shares of the company's stock after selling 11,619 shares during the period. US Bancorp DE's holdings in NewAmsterdam Pharma were worth $72,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of NAMS. Mirae Asset Global Investments Co. Ltd. bought a new position in NewAmsterdam Pharma in the 4th quarter worth $80,000. Quarry LP boosted its stake in shares of NewAmsterdam Pharma by 2,469.2% in the third quarter. Quarry LP now owns 6,500 shares of the company's stock worth $108,000 after acquiring an additional 6,247 shares during the period. Barclays PLC grew its position in shares of NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company's stock worth $126,000 after purchasing an additional 7,199 shares in the last quarter. Bellevue Group AG bought a new stake in NewAmsterdam Pharma during the 3rd quarter valued at approximately $128,000. Finally, XTX Topco Ltd bought a new stake in shares of NewAmsterdam Pharma during the third quarter valued at approximately $187,000. Hedge funds and other institutional investors own 89.89% of the company's stock.

Wall Street Analysts Forecast Growth

NAMS has been the subject of a number of research reports. Scotiabank upped their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Thursday, February 27th. HC Wainwright restated a "buy" rating and set a $48.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Needham & Company LLC decreased their target price on NewAmsterdam Pharma from $46.00 to $42.00 and set a "buy" rating on the stock in a research report on Thursday, February 27th. UBS Group set a $41.00 price target on NewAmsterdam Pharma in a report on Monday, March 3rd. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Six analysts have rated the stock with a buy rating, According to MarketBeat, NewAmsterdam Pharma presently has a consensus rating of "Buy" and an average target price of $43.33.

Remove Ads

NewAmsterdam Pharma Price Performance

Shares of NewAmsterdam Pharma stock traded down $0.24 during trading on Friday, hitting $23.84. The stock had a trading volume of 961,695 shares, compared to its average volume of 508,318. NewAmsterdam Pharma has a 12 month low of $15.19 and a 12 month high of $27.29. The firm's fifty day simple moving average is $21.79 and its 200-day simple moving average is $20.92. The stock has a market cap of $2.62 billion, a PE ratio of -9.17 and a beta of -0.04.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.47). The firm had revenue of $12.77 million during the quarter, compared to analysts' expectations of $3.30 million. Analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Insider Transactions at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the sale, the chief accounting officer now directly owns 15,000 shares in the company, valued at $305,550. The trade was a 90.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director James N. Topper bought 4,005 shares of the company's stock in a transaction on Tuesday, March 4th. The shares were acquired at an average price of $21.02 per share, for a total transaction of $84,185.10. Following the completion of the acquisition, the director now owns 3,012,434 shares in the company, valued at $63,321,362.68. This represents a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 238,416 shares of company stock worth $5,328,104. Insiders own 19.50% of the company's stock.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.